Keeping ‘temporary’ drug rebates is ‘option’ says German HTA
This article was originally published in Scrip
The head of the German pricing and reimbursement body, the G-BA, Josef Hecken, has floated an option with Germany’s health ministry that temporary 10% rebate hikes imposed on pharma earlier this year should be extended in order to keep pharmaceutical costs down until the savings wrought through the new AMNOG pricing and reimbursement system kick in fully.
You may also be interested in...
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
Patient access schemes have helped the Scottish Medicines Consortium recommend rare disease products, including Regeneron/Sanofi’s Libtayo for skin cancer.